Lipiodol will no longer leave the Brazilian market. After two years of struggle, the National Health Surveillance Agency (Anvisa), the Ministry of Health, the Ministry of Education, the Ministry of Finance and a few other Secretariats and Technical Chambers approved the change in indication for the use of Lipiodol after its suitability for the market. By the number of approvals required, it is possible to understand that it was an arduous path.
This process of struggle was a good example of joint work between two societies, the Brazilian Society of Interventional Radiology and Endovascular Surgery (Sobrice) and the Brazilian Society of Diagnostic and Therapeutic Neuroradiology (SBNR), initiated during Dr. Ricardo Augusto de Paula Pinto, with the active collaboration of doctors Alexandre Corvello, Daniel Abud, Gustavo Paludetto and many others who directly or indirectly participated in this work – firstly, pressuring the company and, later, intermediating with the government our interest in maintaining the product on the market. The final victory proved that unity is strength.